Evidence map›Paper›PMID 34257318›Full record

ArticleScientific reports2021

Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation.

Noah T Ventimiglia, Emily M Stucke, Drissa Coulibaly, Andrea A Berry, Kirsten E Lyke, Matthew B Laurens, Jason A Bailey, Matthew Adams, Amadou Niangaly, Abdoulaye K Kone and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Noah T VentimigliaUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Emily M StuckeUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Drissa CoulibalyUniversity of Sciences, Techniques and Technologies, Bamako, Mali.
Andrea A BerryUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Kirsten E LykeUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Matthew B LaurensUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Jason A BaileyUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Matthew AdamsUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Amadou NiangalyUniversity of Sciences, Techniques and Technologies, Bamako, Mali.
Abdoulaye K KoneUniversity of Sciences, Techniques and Technologies, Bamako, Mali.
Shannon Takala-HarrisonUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Bourema KouribaUniversity of Sciences, Techniques and Technologies, Bamako, Mali.
Ogobara K DoumboUniversity of Sciences, Techniques and Technologies, Bamako, Mali.
Phillip L FelgnerUniversity of California, Irvine, CA, USA.
Christopher V PloweUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Mahamadou A TheraUniversity of Sciences, Techniques and Technologies, Bamako, Mali.
Mark A TravassosUniversity of Maryland School of Medicine, Baltimore, MD, USA. mtravass@som.umaryland.edu.
University of Maryland, Baltimore · USUniversité des Sciences, des Techniques et des Technologies de Bamako · MLUniversity of California, Irvine · US

Funding

EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Safety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2005 to 2009
$4.7M
MALARIA RESEARCH TRAINING IN MALID43TW001589 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2000 to 2015
$2.8M
Malaria:Clinical Research and Trial Preparation Sites-26685346N01AI085346 · NIAID · Univ Maryland · 1998 to 2004
$2.8M
Immuno-epidemiological epitope mapping of a blood stage malaria vaccine antigenR01AI093635 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2012 to 2015
$2.3M
Variant surface antigens in cerebral malaria pathogenesisR01HL130750 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI FISHER, STEVEN A., PLOWE, CHRISTOPHER V. · 2015 to 2018
$2.1M
Malaria variant surface antigen expression and vulnerability to disease in Malian children with Hemoglobin C traitR01HL146377 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI TRAVASSOS, MARK A · 2019 to 2023
$1.9M
Protein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915k
Host vulnerability and parasite genetics in the development of cerebral malariaR01AI099628 · NIAID · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI THERA, MAHAMADOU ALI · 2014 to 2018
$625k
FIC NIH HHS D43TW001589NHLBI NIH HHS R01 HL130750NHLBI NIH HHS R01 HL146377NHLBI NIH HHS R01HL146377NIAID NIH HHS K23 AI125720NIAID NIH HHS N01AI85346NIAID NIH HHS R01 AI093635NIGMS NIH HHS R25 GM055036
6 · The paper itself

Abstract

Plasmodium falciparum erythrocyte membrane protein-1s (PfEMP1s), diverse malaria proteins expressed on the infected erythrocyte surface, play an important role in pathogenesis, mediating adhesion to host vascular endothelium. Antibodies to particular non-CD36-binding PfEMP1s are associated with protection against severe disease. We hypothesized that given lifelong P. falciparum exposure, Malian adults would have broad PfEMP1 serorecognition and high seroreactivity levels during follow-up, particularly to non-CD36-binding PfEMP1s such as those that attach to endothelial protein C receptor (EPCR) and intercellular adhesion molecule-1 (ICAM-1). Using a protein microarray, we determined serologic responses to 166 reference PfEMP1 fragments during a dry and subsequent malaria transmission season in Malian adults. Malian adult sera had PfEMP1 serologic responses throughout the year, with decreased reactivity to a small subset of PfEMP1 fragments during the dry season and increases in reactivity to a different subset of PfEMP1 fragments during the subsequent peak malaria transmission season, especially for intracellular PfEMP1 domains. For some individuals, PfEMP1 serologic responses increased after the dry season, suggesting antigenic switching during asymptomatic infection. Adults were more likely to experience variable serorecognition of CD36-binding PfEMP1s than non-CD36-binding PfEMP1s that bind EPCR or ICAM-1, which remained serorecognized throughout the year. Sustained seroreactivity to non-CD36-binding PfEMP1s throughout adulthood amid seasonal fluctuation patterns may reflect underlying protective severe malaria immunity and merits further investigation.

Indexed as

Antibodies, ProtozoanEndothelial Protein C ReceptorIntercellular Adhesion Molecule-1Malaria, FalciparumPlasmodium falciparumProtozoan ProteinsSeasonsAdultFemaleHumansMaleMaliMiddle AgedVirulenceYoung AdultAntibodies, ProtozoanEndothelial Protein C Receptorerythrocyte membrane protein 1, Plasmodium falciparumIntercellular Adhesion Molecule-1PROCR protein, humanProtozoan Proteins

Identifiers

PMID34257318
PMCPMC8277812
OpenAlexW3178305392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.